Drug Approval | February 17, 2026
FDA grants priority review to Bristol Myers Squibb's Iberdomide for multiple myeloma
Iberdomide has the potential to be the first approved CELMoD agent
Iberdomide has the potential to be the first approved CELMoD agent
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
Subscribe To Our Newsletter & Stay Updated
